Halozyme Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Halozyme Therapeutics has a total shareholder equity of $83.8M and total debt of $1.5B, which brings its debt-to-equity ratio to 1788.9%. Its total assets and total liabilities are $1.7B and $1.6B respectively. Halozyme Therapeutics's EBIT is $340.1M making its interest coverage ratio 38.8. It has cash and short-term investments of $336.0M.
Key information
1,788.9%
Debt to equity ratio
US$1.50b
Debt
Interest coverage ratio | 38.8x |
Cash | US$336.00m |
Equity | US$83.81m |
Total liabilities | US$1.65b |
Total assets | US$1.73b |
Recent financial health updates
These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Recent updates
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today
Sep 08Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Aug 16Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off
Aug 03Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jul 26Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Jun 10Halozyme: Antares Pharma Bolsters Growth Prospects
May 19Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Apr 25Financial Position Analysis
Short Term Liabilities: HALO's short term assets ($746.4M) exceed its short term liabilities ($112.5M).
Long Term Liabilities: HALO's short term assets ($746.4M) do not cover its long term liabilities ($1.5B).
Debt to Equity History and Analysis
Debt Level: HALO's net debt to equity ratio (1388%) is considered high.
Reducing Debt: HALO's debt to equity ratio has increased from 50.8% to 1788.9% over the past 5 years.
Debt Coverage: HALO's debt is well covered by operating cash flow (25.9%).
Interest Coverage: HALO's interest payments on its debt are well covered by EBIT (38.8x coverage).